These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 25382188)

  • 1. A novel trial of topotecan, ifosfamide, and carboplatin (TIC) in children with recurrent solid tumors.
    Radhakrishnan K; Lee A; Harrison LA; Morris E; Shen V; Gates L; Wells RJ; Wolff JE; Garvin JH; Cairo MS
    Pediatr Blood Cancer; 2015 Feb; 62(2):274-278. PubMed ID: 25382188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil.
    Loss JF; Santos PP; Leone LD; Brunetto AL
    Pediatr Blood Cancer; 2004 Feb; 42(2):139-44. PubMed ID: 14752877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA; Al Omari A; Murry DJ; Case D
    Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities.
    Bracho F; Krailo MD; Shen V; Bergeron S; Davenport V; Liu-Mares W; Blazar BR; Panoskaltsis-Mortari A; van de Ven C; Secola R; Ames MM; Reid JM; Reaman GH; Cairo MS
    Clin Cancer Res; 2001 Jan; 7(1):58-67. PubMed ID: 11205919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of ifosfamide, carboplatin, and etoposide in children with solid tumors.
    Cairo MS
    Semin Oncol; 1995 Jun; 22(3 Suppl 7):23-7. PubMed ID: 7610395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report.
    Abu-Ghosh AM; Krailo MD; Goldman SC; Slack RS; Davenport V; Morris E; Laver JH; Reaman GH; Cairo MS
    Ann Oncol; 2002 Mar; 13(3):460-9. PubMed ID: 11996479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.
    Schneider CP; Merkel U; Grübner U; Kath R; Höffken K; Hoffmann A
    J Cancer Res Clin Oncol; 2002 Jun; 128(6):313-8. PubMed ID: 12073049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy.
    Marina NM; Shema SJ; Bowman LC; Rodman J; Douglass EC; Furman WL; Pappo A; Santana VM; Hudson M; Meyer WH
    Med Pediatr Oncol; 1994; 23(4):328-34. PubMed ID: 8058003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors.
    Marina NM; Rodman JH; Murry DJ; Shema SJ; Bowman LC; Jones DP; Furman W; Meyer WH; Pratt CB
    J Natl Cancer Inst; 1994 Apr; 86(7):544-8. PubMed ID: 8133538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience.
    Van Winkle P; Angiolillo A; Krailo M; Cheung YK; Anderson B; Davenport V; Reaman G; Cairo MS
    Pediatr Blood Cancer; 2005 Apr; 44(4):338-47. PubMed ID: 15503297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
    Cairo MS; Davenport V; Bessmertny O; Goldman SC; Berg SL; Kreissman SG; Laver J; Shen V; Secola R; van de Ven C; Reaman GH
    Br J Haematol; 2005 Jan; 128(1):49-58. PubMed ID: 15606549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
    Griffin TC; Weitzman S; Weinstein H; Chang M; Cairo M; Hutchison R; Shiramizu B; Wiley J; Woods D; Barnich M; Gross TG;
    Pediatr Blood Cancer; 2009 Feb; 52(2):177-81. PubMed ID: 18816698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age.
    Donfrancesco A; Jenkner A; Castellano A; Ilari I; Milano GM; De Sio L; Cozza R; Fidani P; Deb G; De Laurentis C; Inserra A; Dominici C
    Acta Paediatr Suppl; 2004 May; 93(445):6-11. PubMed ID: 15176712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme.
    Aoki T; Mizutani T; Nojima K; Takagi T; Okumura R; Yuba Y; Ueba T; Takahashi JA; Miyatake S; Nozaki K; Taki W; Matsutani M
    J Neurosurg; 2010 Jan; 112(1):50-6. PubMed ID: 19538050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
    Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
    Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas.
    Zhou P; Liu P; Zhou SY; He XH; Han XH; Qin Y; Yang S; Zhang CG; Gui L; Yao JR; Zhao LY; Zhang SX; Sun Y; Shi YK
    Chin Med J (Engl); 2015 Sep; 128(18):2498-504. PubMed ID: 26365969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study.
    Kung FH; Desai SJ; Dickerman JD; Goorin AM; Harris MB; Inoue S; Krischer JP; Murphy SB; Pratt CB; Toledano S
    J Pediatr Hematol Oncol; 1995 Aug; 17(3):265-9. PubMed ID: 7620926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.